It was reported on September 25 that the U.S. FDA has accepted and granted Priority Review to AstraZeneca PLC (NYSE:AZN)’s supplemental Biologics License Application (sBLA) for IMFINZI (durvalumab) in combination with enfortumab vedotin (EV). The regimen treats muscle-invasive bladder cancer (MIBC) in patients ineligible for or declining cisplatin-based chemotherapy. Supported by Phase III VOLGA trial results showing statistically significant improvements in event-free and overall survival, an FDA regulatory decision is expected in Q4 2026.
This acceptance reinforces AstraZeneca’s momentum following strong H1 2026 performance, where total revenue grew 6% at constant exchange rates (CER) and core operating profit and core EPS rose 11%, driven by double-digit expansion in Oncology and Rare Disease.
You Might Also Want To Read: AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Approved for NHS Use in England
Bull Case: Expanding Oncology Franchise and Pipeline Execution
AstraZeneca PLC’s broad oncology portfolio continues to deliver strong top-line momentum, helping absorb market pressure elsewhere. Securing Priority Review for IMFINZI validates management’s strategy to turn the drug into an immunotherapy backbone across major cancer types. Approval would establish the first perioperative regimen featuring neoadjuvant EV for this high-need patient segment, expanding IMFINZI’s addressable market.
This clinical win aligns with AstraZeneca’s robust commercial baseline. In H1 2026, the company logged 30 major regional approvals while reconfirming full-year FY 2026 guidance for mid-to-high single-digit revenue growth and low double-digit Core EPS growth. High operating margins and sustained double-digit oncology growth demonstrate that high-value pipeline readouts can effectively offset maturity headwinds, securing long-term earnings growth.
Bear Case: Exclusivity Losses, Debt Load, and Clinical Risks
Despite pipeline progress, AstraZeneca faces ongoing top-line drag from mature assets. Loss of exclusivity for Farxiga in the U.S. and volume-based procurement (VBP) pressures in China continue to weigh on performance, restricting overall revenue growth to 6% in H1 2026 despite strong oncology demand.
To maintain its growth trajectory, AstraZeneca relies heavily on flawless clinical execution. Late-stage oncology development carries inherent risks where trial failures or regulatory delays can abruptly alter cash projections. Furthermore, a sizeable debt load and partial earnings-to-cash conversion limit financial flexibility. If new commercial launches like the expanded IMFINZI combination encounter adoption hurdles or delayed rollouts, elevated financing costs and dividend commitments could constrain reinvestment into earlier-stage assets.
Don’t Miss: AstraZeneca (AZN) Wins FDA Approval for its Breast Cancer Pill After Regulators Voiced Doubts
Conclusion
The FDA Priority Review is a clear operational catalyst for AstraZeneca PLC, bolstering its high-margin oncology pipeline as legacy products face structural decline. While generic pressure on Farxiga and leverage metrics require careful monitoring, AstraZeneca’s 11% Core EPS growth and reaffirmed 2026 guidance highlight durable fundamentals. The IMFINZI combination reinforces the bull thesis that robust R&D execution can successfully drive sustainable revenue growth.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
